Erythropoietin + Iron Therapy for Anemic Patients Undergoing Aortic Valve Replacement
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate the efficacy of Erythropoietin (EPO) (+ iron) in
reducing the rate of red blood cell transfusion requirements in patients with aortic stenosis
undergoing transcatheter aortic valve replacement.
Phase:
Phase 3
Details
Lead Sponsor:
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec